1,478
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Costs of breast cancer recurrence after initial treatment for HR+, HER2−, high-risk early breast cancer: estimates from SEER-Medicare linked data

, , , , , & show all
Pages 84-96 | Received 08 Jun 2023, Accepted 01 Dec 2023, Published online: 19 Dec 2023

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.